Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation
G Zhang, MA Park, C Mitchell, H Hamed… - Clinical cancer …, 2008 - AACR
Abstract Purpose and Design: Mechanism (s) by which the multikinase inhibitor sorafenib
and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal, and pancreatic …
and the histone deacetylase inhibitor vorinostat interact to kill hepatic, renal, and pancreatic …
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation
MA Park, G Zhang, AP Martin, H Hamed… - Cancer biology & …, 2008 - Taylor & Francis
We recently noted that low doses of sorafenib and vorinostat interact in a synergistic fashion
to kill carcinoma cells by activating CD95, and this drug combination is entering phase I …
to kill carcinoma cells by activating CD95, and this drug combination is entering phase I …
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and-independent mechanisms
T Walker, C Mitchell, MA Park, A Yacoub, M Graf… - Molecular …, 2009 - ASPET
We examined the interaction between the multikinase inhibitor sorafenib and histone
deacetylase inhibitors. Sorafenib and vorinostat synergized (sorafenib+ vorinostat) to kill …
deacetylase inhibitors. Sorafenib and vorinostat synergized (sorafenib+ vorinostat) to kill …
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells
MA Park, R Reinehr, D Häussinger… - Molecular cancer …, 2010 - AACR
Sorafenib and vorinostat interact in a synergistic fashion to kill carcinoma cells by activating
CD95; the present studies have determined how sorafenib and vorinostat individually …
CD95; the present studies have determined how sorafenib and vorinostat individually …
Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells through a Ca2+-De novo Ceramide-PP2A-Reactive Oxygen Species–Dependent …
MA Park, C Mitchell, G Zhang, A Yacoub, J Allegood… - Cancer research, 2010 - AACR
The targeted therapeutics sorafenib and vorinostat interact in a synergistic fashion to kill
carcinoma cells by activating CD95, and this drug combination is entering phase I …
carcinoma cells by activating CD95, and this drug combination is entering phase I …
Combination of wogonin and sorafenib effectively kills human hepatocellular carcinoma cells through apoptosis potentiation and autophagy inhibition
LW Rong, RX Wang, XL Zheng… - Oncology …, 2017 - spandidos-publications.com
The small molecule multi-kinase inhibitor sorafenib has become the standard systemic
treatment for patients with advanced hepatocellular carcinoma (HCC) and renal cell …
treatment for patients with advanced hepatocellular carcinoma (HCC) and renal cell …
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing
AP Martin, MA Park, C Mitchell, T Walker… - Molecular …, 2009 - ASPET
We examined whether the multikinase inhibitor sorafenib and histone deacetylase inhibitors
(HDACI) interact to kill pancreatic carcinoma cells and determined the impact of inhibiting …
(HDACI) interact to kill pancreatic carcinoma cells and determined the impact of inhibiting …
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling
Sorafenib is effective for patients with advanced hepatocellular carcinoma (HCC) and
particularly for those who are unsuitable to receive life-prolonging transarterial …
particularly for those who are unsuitable to receive life-prolonging transarterial …
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms
D Llobet, N Eritja, A Yeramian, J Pallares… - European Journal of …, 2010 - Elsevier
Sorafenib induces apoptosis and enhances Tumour Necrosis Factor-Related Apoptosis-
Inducing Ligand (TRAIL)-induced cell killing of tumoural cells. We have investigated the …
Inducing Ligand (TRAIL)-induced cell killing of tumoural cells. We have investigated the …
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2 …
C Yu, BB Friday, JP Lai, L Yang, J Sarkaria… - Molecular cancer …, 2006 - AACR
This study was undertaken to characterize preclinical cytotoxic interactions for human
malignancies between the multikinase inhibitor sorafenib (BAY 43-9006) and proteasome …
malignancies between the multikinase inhibitor sorafenib (BAY 43-9006) and proteasome …
相关搜索
- vorinostat and sorafenib cd95 activation
- vorinostat and sorafenib tumor cells
- tumor cells cd95 activation
- carcinoma cells jnk activation
- vorinostat and sorafenib signaling pathway
- signaling pathway cd95 activation
- signaling pathway tumor cells
- vorinostat and sorafenib oxygen species
- oxygen species cd95 activation
- oxygen species tumor cells
- vorinostat and sorafenib perk activation